Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Highlights from AAO 2026
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology annual meeting.
In an interview, David R.P. Almeida, MD, MBA, PhD, presented the findings of the phase 4 SYNCHRONICITY study of fluocinolone acetonide intravitreal implant 0.18 mg in patients with noninfectious uveitis affecting the posterior segment.
Ali Tafreshi, CEO of Oku, talks about how they will use a network of more than 10,000 healthcare locations for early disease detection through routine eye exams and how their primary goal is to use this emerging field to address the healthcare cost crisis in the U.S. and globally.
Next, Jay S. Pepose, MD, PhD, discusses how determining the dominant eye should be one part of monovision planning but not the deciding rule on eye assignment.
Dilraj Grewal, MD, highlights phase 2 and phase 3 data in age-related macular degeneration. He also discusses subretinal and intravitreal delivery of gene therapy in neovascular AMD and potentially in geographic atrophy.
And, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy.
Read the full coverage here:
Fluocinolone 0.18 mg has sustained improvements in noninfectious posterior segment uveitis
Oku Digital Health uses eye care to detect diseases earlier
Monovision planning not always tied to eye dominance
Continued development may fulfill unmet needs in retina
Early use of geographic atrophy drugs provides longer protection of vision